Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of PLH-2301 in Subjects With Sarcopenia
Sponsor: Pluto Inc.
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Official title: A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
168
Start Date
2026-05-08
Completion Date
2027-06-30
Last Updated
2026-05-12
Healthy Volunteers
No
Conditions
Interventions
PLH-2301
PLH-2301 administered orally according to assigned dosing regimen.
Placebo
Matching placebo administered orally according to assigned dosing regimen.
Locations (5)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Korea University Anam Hospital
Seoul, Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, Seoul, South Korea
Korea University Guro Hospital
Seoul, Seoul, South Korea